title: Phenotypical and functional analysis of intraepithelial lymphocytes from small intestine of mice in oral tolerance.
abstract: In this work, we evaluated the effects of administration of OVA on phenotype and function of intraepithelial lymphocytes (IELs) from small intestine of transgenic (TGN) DO11.10 and wild-type BALB/c mice. While the small intestines from BALB/c presented a well preserved structure, those from TGN showed an inflamed aspect. The ingestion of OVA induced a reduction in the number of IELs in small intestines of TGN, but it did not change the frequencies of CD8(+) and CD4(+) T-cell subsets. Administration of OVA via oral + ip increased the frequency of CD103(+) cells in CD4(+) T-cell subset in IELs of both BALB/c and TGN mice and elevated its expression in CD8β(+) T-cell subset in IELs of TGN. The frequency of Foxp3(+) cells increased in all subsets in IELs of BALB/c treated with OVA; in IELs of TGN, it increased only in CD25(+) subset. IELs from BALB/c tolerant mice had lower expression of all cytokines studied, whereas those from TGN showed high expression of inflammatory cytokines, especially of IFN-γ, TGF-β, and TNF-α. Overall, our results suggest that the inability of TGN to become tolerant may be related to disorganization and altered proportions of inflammatory/regulatory T cells in its intestinal mucosa.
authors.affiliation: Department of Genetics, Evolution and Bioagents, Institute of Biology, University of Campinas, Rua Monteiro Lobato of 255, CP 6109, 13083-970 Campinas, SP, Brazil.
authors.forename: Maristela
authors.initials: M
authors.lastname: Ruberti
authors.forename: Luis Gustavo Romani
authors.initials: LG
authors.lastname: Fernandes
authors.forename: Patricia Ucelli
authors.initials: PU
authors.lastname: Simioni
authors.forename: Dirce Lima
authors.initials: DL
authors.lastname: Gabriel
authors.forename: Aureo Tatsumi
authors.initials: AT
authors.lastname: Yamada
authors.forename: Wirla Maria da Silva Cunha
authors.initials: WM
authors.lastname: Tamashiro
mesh_terms: D000284:Administration, Oral; D000818:Animals; D015703:Antigens, CD / Q000096:biosynthesis / Q000276:immunology; D015496:CD4-Positive T-Lymphocytes / Q000166:cytology / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000166:cytology / Q000276:immunology; D004847:Epithelial Cells / Q000166:cytology / Q000187:drug effects / Q000276:immunology*; D007108:Immune Tolerance / Q000187:drug effects*; D007274:Injections, Intraperitoneal; D007371:Interferon-gamma / Q000096:biosynthesis / Q000276:immunology; D007421:Intestine, Small / Q000166:cytology / Q000187:drug effects / Q000276:immunology*; D018655:Lymphocyte Count; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008822:Mice, Transgenic; D010047:Ovalbumin / Q000008:administration & dosage / Q000276:immunology*; D016176:T-Lymphocyte Subsets / Q000187:drug effects* / Q000276:immunology; D016212:Transforming Growth Factor beta / Q000096:biosynthesis / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis / Q000276:immunology
chemical_list: D015703:Antigens, CD; D016212:Transforming Growth Factor beta; D014409:Tumor Necrosis Factor-alpha; D007371:Interferon-gamma; D010047:Ovalbumin